附註:"Prepared for the Office of the Secretary of Defense."
"This executive summary reproduces the preface and summary from Pyridostigmine bromide by Beatrice Alexandra Golomb, MR-1018/2-OSD"--Title page verso.
"MR-1018/2/1-OSD"--Page 4 of cover.
Includes bibliographical references.
Ch. 1. Introduction -- Ch. 2. Fact Sheet: PB Pretreatment for Soman Exposure -- Ch. 3. Characteristics of PB -- Ch. 4. PB Use in the Persian Gulf War -- Ch. 5. Health Problems in PGW Veterans -- Ch. 6. Theories Linking PB to Illness in PGW Veterans -- Ch. 7. Blood-Brain Barrier Passage -- Ch. 8. Individual Differences in Reactions to PB -- Ch. 9. Interactions between PB and other Exposures -- Ch. 10. Bromism -- Ch. 11. Multiple Chemical Sensitivity -- Ch. 12. Neuromuscular Junction Effects -- Ch. 13. Neurotransmitter Dysregulation -- Ch. 14. Chronic Effects -- Ch. 15. Other Considerations -- Ch. 16. Conclusions -- Addendum: Evidence for Neurotransmitter Dysregulation Identified or Published Since the Review Process -- App. A. Pyridostigmine Pharmacokinetic Data -- App. B. Effects of PB in Humans -- App. C. Further Discussion of the Acetylcholine-Serotonin Relationship.
摘要:The United States and its allies in the Persian Gulf War (PGW) knew that Iraq had used nerve agents and chemical weapons in its previous conflicts and so took steps to protect their troops. Pyridostigmine bromide (PB) was distributed as a pretreatment that would enhance the effectiveness of postexposure treatments in the event that the nerve agent soman was used. This report examines the role that PB played in the ongoing chronic health problems documented in PGW veterans. After careful examination of the known effects of PB on the central and peripheral nervous systems, the author finds the evidence consistent with a possible role for PB as a contributor to the health complaints of some PGW veterans and calls for immediate attention in the form of additional investigation to clarify the role of PB. -- Provided by publisher.
